Summary
Global Markets Direct’s, ‘Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2016’, provides an overview of the Refractory Chronic Lymphocytic Leukemia (CLL) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Refractory Chronic Lymphocytic Leukemia (CLL), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Refractory Chronic Lymphocytic Leukemia (CLL) and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Refractory Chronic Lymphocytic Leukemia (CLL)
- The report reviews pipeline therapeutics for Refractory Chronic Lymphocytic Leukemia (CLL) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Refractory Chronic Lymphocytic Leukemia (CLL) therapeutics and enlists all their major and minor projects
- The report assesses Refractory Chronic Lymphocytic Leukemia (CLL) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Refractory Chronic Lymphocytic Leukemia (CLL)
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Refractory Chronic Lymphocytic Leukemia (CLL)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Refractory Chronic Lymphocytic Leukemia (CLL) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
4SC AG
AbbVie Inc.
Arno Therapeutics, Inc.
Astellas Pharma Inc.
Astex Pharmaceuticals, Inc.
AstraZeneca Plc
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Celgene Corporation
Cellular Biomedicine Group, Inc.
F. Hoffmann-La Roche Ltd.
Hutchison MediPharma Limited
ImmunoGen, Inc.
Immunomedics, Inc.
Incyte Corporation
Infinity Pharmaceuticals, Inc.
Innate Pharma S.A.
Juno Therapeutics Inc.
Karyopharm Therapeutics, Inc.
Les Laboratoires Servier SAS
LFB S.A.
Lymphocyte Activation Technologies, S.A.
Medicenna Therapeutics, Inc.
Millennium Pharmaceuticals, Inc.
MorphoSys AG
Novartis AG
Oncternal Therapeutics, Inc.
Ono Pharmaceutical Co., Ltd.
Portola Pharmaceuticals, Inc.
Sanofi
TG Therapeutics, Inc.
Threshold Pharmaceuticals, Inc.
Tragara Pharmaceuticals, Inc.
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Refractory Chronic Lymphocytic Leukemia (CLL) Overview 8
Therapeutics Development 9
Pipeline Products for Refractory Chronic Lymphocytic Leukemia (CLL) - Overview 9
Pipeline Products for Refractory Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis 10
Refractory Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Development by Companies 11
Refractory Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Investigation by Universities/Institutes 13
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Refractory Chronic Lymphocytic Leukemia (CLL) - Products under Development by Companies 17
Refractory Chronic Lymphocytic Leukemia (CLL) - Products under Investigation by Universities/Institutes 20
Refractory Chronic Lymphocytic Leukemia (CLL) - Companies Involved in Therapeutics Development 21
4SC AG 21
AbbVie Inc. 22
Arno Therapeutics, Inc. 23
Astellas Pharma Inc. 24
Astex Pharmaceuticals, Inc. 25
AstraZeneca Plc 26
Boehringer Ingelheim GmbH 27
Bristol-Myers Squibb Company 28
Celgene Corporation 29
Cellular Biomedicine Group, Inc. 30
F. Hoffmann-La Roche Ltd. 31
Hutchison MediPharma Limited 32
ImmunoGen, Inc. 33
Immunomedics, Inc. 34
Incyte Corporation 35
Infinity Pharmaceuticals, Inc. 36
Innate Pharma S.A. 37
Juno Therapeutics Inc. 38
Karyopharm Therapeutics, Inc. 39
Les Laboratoires Servier SAS 40
LFB S.A. 41
Lymphocyte Activation Technologies, S.A. 42
Medicenna Therapeutics, Inc. 43
Millennium Pharmaceuticals, Inc. 44
MorphoSys AG 45
Novartis AG 46
Oncternal Therapeutics, Inc. 47
Ono Pharmaceutical Co., Ltd. 48
Portola Pharmaceuticals, Inc. 49
Sanofi 50
TG Therapeutics, Inc. 51
Threshold Pharmaceuticals, Inc. 52
Tragara Pharmaceuticals, Inc. 53
Refractory Chronic Lymphocytic Leukemia (CLL) - Therapeutics Assessment 54
Assessment by Monotherapy Products 54
Assessment by Combination Products 55
Assessment by Target 56
Assessment by Mechanism of Action 59
Assessment by Route of Administration 62
Assessment by Molecule Type 64
Drug Profiles 66
(INCB-039110 + INCB-040093) - Drug Profile 66
4SC-202 - Drug Profile 67
acalabrutinib - Drug Profile 69
ACP-319 - Drug Profile 72
afuresertib hydrochloride - Drug Profile 73
AGS-67E - Drug Profile 76
AR-42 - Drug Profile 78
AT-7519 - Drug Profile 80
AZD-6738 - Drug Profile 83
BI-836826 - Drug Profile 85
BMS-986016 - Drug Profile 87
buparlisib hydrochloride - Drug Profile 88
CBM-C19.1 - Drug Profile 92
CBM-C20.1 - Drug Profile 93
CC-122 - Drug Profile 95
Cellular Immunotherapy for Chronic Lymphocytic Leukemia - Drug Profile 97
Cellular Immunotherapy to Target Receptor Tyrosine Kinase-Like Orphan Receptor 1 for Chronic Lymphocytic Leukemia - Drug Profile 98
cerdulatinib - Drug Profile 99
duvelisib - Drug Profile 101
evofosfamide - Drug Profile 104
HMPL-523 - Drug Profile 112
IMGN-529 - Drug Profile 113
IMMU-114 - Drug Profile 115
JCAR-014 - Drug Profile 116
JCAR-015 - Drug Profile 117
lirilumab - Drug Profile 119
MDNA-56 - Drug Profile 121
monalizumab - Drug Profile 122
MOR-208 - Drug Profile 124
nivolumab - Drug Profile 126
obinutuzumab - Drug Profile 134
pilaralisib - Drug Profile 138
S-055746 - Drug Profile 141
selinexor - Drug Profile 142
spebrutinib besylate - Drug Profile 148
TAK-659 - Drug Profile 150
TG-02 - Drug Profile 151
TGR-1202 - Drug Profile 154
tisagenlecleucel-T - Drug Profile 157
ublituximab - Drug Profile 160
UC-961 - Drug Profile 163
ulocuplumab - Drug Profile 164
urelumab - Drug Profile 166
venetoclax - Drug Profile 168
Refractory Chronic Lymphocytic Leukemia (CLL) - Recent Pipeline Updates 172
Refractory Chronic Lymphocytic Leukemia (CLL) - Dormant Projects 271
Refractory Chronic Lymphocytic Leukemia (CLL) - Discontinued Products 273
Refractory Chronic Lymphocytic Leukemia (CLL) - Product Development Milestones 274
Featured News & Press Releases 274
Appendix 282
Methodology 282
Coverage 282
Secondary Research 282
Primary Research 282
Expert Panel Validation 282
Contact Us 282
Disclaimer 283
List of Tables
Number of Products under Development for Refractory Chronic Lymphocytic Leukemia (CLL), H1 2016 12
Number of Products under Development for Refractory Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis, H1 2016 13
Number of Products under Development by Companies, H1 2016 14
Number of Products under Development by Companies, H1 2016 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H1 2016 16
Comparative Analysis by Late Stage Development, H1 2016 17
Comparative Analysis by Clinical Stage Development, H1 2016 18
Comparative Analysis by Early Stage Development, H1 2016 19
Products under Development by Companies, H1 2016 20
Products under Development by Companies, H1 2016 (Contd..1) 21
Products under Development by Companies, H1 2016 (Contd..2) 22
Products under Investigation by Universities/Institutes, H1 2016 23
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by 4SC AG, H1 2016 24
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by AbbVie Inc., H1 2016 25
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Arno Therapeutics, Inc., H1 2016 26
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Astellas Pharma Inc., H1 2016 27
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Astex Pharmaceuticals, Inc., H1 2016 28
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by AstraZeneca Plc, H1 2016 29
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Boehringer Ingelheim GmbH, H1 2016 30
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Bristol-Myers Squibb Company, H1 2016 31
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Celgene Corporation, H1 2016 32
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Cellular Biomedicine Group, Inc., H1 2016 33
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 34
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Hutchison MediPharma Limited, H1 2016 35
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by ImmunoGen, Inc., H1 2016 36
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Immunomedics, Inc., H1 2016 37
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Incyte Corporation, H1 2016 38
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Infinity Pharmaceuticals, Inc., H1 2016 39
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Innate Pharma S.A., H1 2016 40
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Juno Therapeutics Inc., H1 2016 41
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Karyopharm Therapeutics, Inc., H1 2016 42
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Les Laboratoires Servier SAS, H1 2016 43
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by LFB S.A., H1 2016 44
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Lymphocyte Activation Technologies, S.A., H1 2016 45
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Medicenna Therapeutics, Inc., H1 2016 46
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016 47
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by MorphoSys AG, H1 2016 48
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Novartis AG, H1 2016 49
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Oncternal Therapeutics, Inc., H1 2016 50
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016 51
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Portola Pharmaceuticals, Inc., H1 2016 52
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Sanofi, H1 2016 53
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by TG Therapeutics, Inc., H1 2016 54
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Threshold Pharmaceuticals, Inc., H1 2016 55
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Tragara Pharmaceuticals, Inc., H1 2016 56
Assessment by Monotherapy Products, H1 2016 57
Assessment by Combination Products, H1 2016 58
Number of Products by Stage and Target, H1 2016 60
Number of Products by Stage and Mechanism of Action, H1 2016 63
Number of Products by Stage and Route of Administration, H1 2016 66
Number of Products by Stage and Molecule Type, H1 2016 68
Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics - Recent Pipeline Updates, H1 2016 175
Refractory Chronic Lymphocytic Leukemia (CLL) - Dormant Projects, H1 2016 274
Refractory Chronic Lymphocytic Leukemia (CLL) - Dormant Projects (Contd..1), H1 2016 275
Refractory Chronic Lymphocytic Leukemia (CLL) - Discontinued Products, H1 2016 276
List of Figures
Number of Products under Development for Refractory Chronic Lymphocytic Leukemia (CLL), H1 2016 12
Number of Products under Development for Refractory Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis, H1 2016 13
Number of Products under Development by Companies, H1 2016 14
Comparative Analysis by Late Stage Development, H1 2016 17
Comparative Analysis by Clinical Stage Development, H1 2016 18
Assessment by Monotherapy Products, H1 2016 57
Number of Products by Top 10 Targets, H1 2016 59
Number of Products by Stage and Top 10 Targets, H1 2016 59
Number of Products by Top 10 Mechanism of Actions, H1 2016 62
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 62
Number of Products by Routes of Administration, H1 2016 65
Number of Products by Stage and Routes of Administration, H1 2016 65
Number of Products by Molecule Types, H1 2016 67
Number of Products by Stage and Molecule Types, H1 2016 67
